Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Nick Lydon

Chris Varma

Brian Druker

Alexis Borisy

Blueprint Medicines Corporation

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

VC Lab is a venture capital accelerator that helps managers worldwide close on capital in under 6 months. It also offers training programs for accredited investors and aspiring professionals in the venture capital industry.

Metric
Company Name	Blueprint Medicines Corporation	Ardelyx, Inc.	VC Lab
Symbol	BPMC	ARDX
MSH ID	COM:BLUEPRINTMEDICINES	COM:ARDELYX	COM:GOVCLAB
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Financial Services & Finance
Industry	Biotechnology	Biotechnology	Venture Capital
Country	US	US	US
Stage		Debt	Pre Seed
Employee Count	645	267
Website	blueprintmedicines.com	ardelyx.com	govclab.com
LinkedIn
Founders

Metric
Market Cap	7.26B	1.30B
Enterprise Value
Monthly Web Traffic		33.50K
Web Traffic Growth		2.80
Valuation
Raised Capital		20M

Metric
Revenue	249.38M	124.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	224.92M	106.66M
EBITDA	-474.61M	-55.35M
Operating Income	-486.28M	-63.28M
Net Income	-506.98M	-66.07M
EPS	-8.37	-0.30
Diluted EPS	-8.37	-0.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.96	0.86
Operating Profit Margin	-0.98	-0.28
EBITDA Margin	-1.90	-0.44
Net Profit Margin	-0.57	-0.31
Return on Equity	-0.85	-0.40
Return on Assets	-0.17	-0.19
Return on Capital Employed	-0.37	-0.21

COM:BLUEPRINTMEDICINES

Blueprint Medicines

Last Close

96.62

22/11 21:00

Market Cap

7.26B

Beta: -

Volume Today

663.53K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.39	-74.58
P/B Ratio	22.98	10.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	26.58	14.47
EV Multiple	-9.68	-20.25

Metric
Days Sales Outstanding	69.65	117.61
Days Payables Outstanding	170.58	185.33
Days Inventory Outstanding	952.36	264.91
Operating Cycle	1.03K	329.52
Cash Conversion Cycle	878.40	100.07
Asset Turnover	0.30	0.61

Metric
Operating Cash Flow	-436.85M	-89.72M
Free Cash Flow	-452.91M	-90.06M
Cash Flow to Debt	-0.50	-0.77
Operating Cash Flow/Sales	-0.92	-0.41
Free Cash Flow Yield	-0.11	-0.03

Metric
Cash & Equivalents	71.29M	21.47M
Accounts Receivable	-7.65M	-14.30M
Inventory	21.22M	12.45M
Goodwill
Debt to Capitalization	0.84	0.41
Debt to Assets	0.11	0.12
Current Ratio	4.09	5.54
Quick Ratio	3.65	4.36

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.44	0.09
R&D to Revenue	2.08	0.26
SG&A to Revenue	0.51	0.15